Insulet (Nasdaq:PODD) today announced new Omnipod 5 clinical data highlighting the transition from multiple daily injections (MDI). Investigators shared data from the RADIANT study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. The randomized controlled trial evaluated the direct transition from MDI to automated insulin delivery (AID). Insulet […]
Featured
Tandem has positive data for automated insulin delivery in type 2 diabetes population
Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for type 2 diabetes. San Diego-based Tandem won FDA clearance for its Control-IQ+ next-generation algorithm for type 2 diabetes at the end of last month. Just yesterday, the company announced the launch of the algorithm. Control-IQ+ represents the next generation of the […]
Dexcom CGM now connects with Novo Nordisk smart insulin pens, 15-day CGM shows promise
![The NovoPen Echo smart insulin pen now works with Dexcom CGM. [Image from Novo Nordisk]](https://www.drugdeliverybusiness.com/wp-content/uploads/2022/11/Novo-Nordisk-NovoPen-Echo-Smart-Insulin-Pen-Abbott-150x86.jpg)
Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors (CGMs). The company shared its updates at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam. It also revealed new findings about attitudes toward the use of technology in the type 2 diabetes population. Today, […]
Dexcom study finds that providers prefer tech over medication for type 2 diabetes
Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments. The “Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East” surveyed 2,500 people. It featured individuals with type 2 diabetes and healthcare professionals across Germany, Italy, the Netherlands, Saudi Arabia, Spain and the […]
Tandem Diabetes Care introduces next-gen automated insulin delivery algorithm
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in the U.S. Control-IQ+ represents the next generation of the company’s advanced hybrid closed-loop insulin delivery algorithm. It has compatibility with both the company’s pump offerings, the t:slim X2 and Mobi pumps. The company said the algorithm is now available for people […]
Ypsomed, CamDiab launch iOS app for automated insulin delivery system
Ypsomed and CamDiab today announced the launch of the mylife CamAPS FX app for automated insulin delivery on iOS platforms. The app comprises part of the mylife Loop automated insulin delivery system. The iOS launch allows people with type 1 diabetes to easily and discreetly manage their pump on iPhones. Ypsomed and CamDiab plan to […]
Insulet CTO Mark Field departs for new opportunities
Insulet (Nasdaq:PODD) announced today that SVP and Chief Technology Officer Mark Field is departing the company. Field left the automated insulin delivery technology developer to pursue other opportunities, effective March 14, according to an SEC filing. As the company searches for Field’s successor, it tapped Amit Guliani to hold the post of interim CTO, effective […]
Insulet expands Omnipod 5 to more countries, prices $450M offering
Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new geographies. The company made Omnipod 5 available in Australia and has planned launches for Belgium, Canada and Switzerland in the near term. This follows the launch of Omnipod 5 in five new European countries at the start […]
Sequel Med Tech makes first CGM integration with Abbott for automated insulin pump
Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor. This marks the first continuous glucose monitor (CGM) integration for twiist. Manchester, New Hampshire-based Sequel expects to launch the combination in the second quarter of 2025. Sequel won FDA clearance for the twiist […]
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 clinical trial. This news comes just one day after Vivani announced plans to spin off its neurostimulation business to focus on its GLP-1 implants. The company also announced full enrollment in LIBERATE-1, achieved in just four weeks after the […]
